PENNINGTON BIOMEDICAL RESEARCH CENTER
LSU

Statement of Cash Flows

For the Year Ended June 30, 2017

Cash flows from operating activities		
Student tuition and fees	$	-
Federal appropriations		-
ARRA receipts		-
Grants and contracts		26,938,049
Sales and services of educational departments		685,535
Hospital income		-
Auxiliary enterprise receipts		103,325
Payments for employee compensation		(25,092,772)
Payments for benefits		(9,371,929)
Payments for utilities		(1,732,356)
Payments for supplies and services		(12,596,498)
Payments for scholarships and fellowships		-
Loans to students		-
Collection of loans to students		-
Other receipts (disbursements)		(223,298)
Net cash provided (used) by operating activities		(21,289,944)
Cash flows from non-capital financing activities		
State appropriations		15,986,374
Transfer to/from other System Institutions		-
Gifts and grants for other than capital purposes		2,813,883
Private gifts for endowment purposes		55,607
TOPS receipts		-
TOPS disbursements		-
FEMA receipts		-
FEMA disbursements		-
ARRA receipts		-
Direct lending receipts		-
Direct lending disbursements		-
Federal Family Education Loan Program receipts		-
Federal Family Education Loan Program disbursements		-
Implicit loan to/from other campuses		-
Other receipts (disbursements)		-
Net cash provided (used) by noncapital financing sources		18,855,864
Cash flows from capital financing activities		
Proceeds from capital debt		-
Capital appropriations received		-
Capital grants and gifts received		(59,918)
Proceeds from sale of capital assets		-
Purchase of capital assets		(358,409)
Principal paid on capital debt and leases		-
Interest paid on capital debt and leases		-
Deposit with trustees		-
Other sources		(27,353)
Net cash provided (used) by capital financing activities		(445,680)

PENNINGTON BIOMEDICAL RESEARCH CENTER LSU

Statement of Cash Flows

For the Year Ended June 30, 2017

Cash flows from investing activities		
Proceeds from sales and maturities of investments		-
Interest received on investments		119,457
Purchase of investments		-
Net cash provided (used) by investing activities		119,457
Net increase (decrease) in cash and cash equivalents		(2,760,303)
Cash and cash equivalents at the beginning of the year		14,954,920
Cash and cash equivalents at the end of the year	$	12,194,617
Reconciliation of Net Operating Revenues (Expenses) to Net Cash Provided (used) by Operating Activities		
Operating loss	$	(20,619,910)
Adjustments to reconcile net income (loss) to net cash provided (used) by operating activities:		
Depreciation expense		5,670,704
Nonemployer contributing entity revenue		157,352
Changes in assets and liabilities		
(Increase) decrease in accounts receivable, net		(2,846,666)
(Increase) decrease in inventories		4,404
(Increase) decrease in prepaid expenses & advances		-
(Increase) decrease in notes receivable		-
(Increase) decrease in deferred outflows related to pensions		(4,174,485)
(Increase) decrease in other assets		-
Increase (decrease) in accounts payable & accrued liabilities		118,774
Increase (decrease) in unearned revenues		(3,766,804)
Increase (decrease) in amounts held in custody for others		-
Increase (decrease) in compensated absences		171,941
Increase (decrease) in OPEB payable		1,734,054
Increase (decrease) in NPL		(46,652)
Increase (decrease) in deferred inflows related to pensions		2,596,473
Increase (decrease) in other liabilities		(289,129)
Net cash provided (used) by operating activities:		(21,289,944)
Noncash Investing, Noncapital Financing, and Capital & Related Financing Transactions		
Capital appropriations		940,825
Capital gifts and grants		-
Net non-cash transactions		940,825

PENNINGTON BIOMEDICAL RESEARCH CENTER LSU

Statement of Cash Flows

For the Year Ended June 30, 2017

Reconciliation of Cash & Cash Equivalents to the SNP		
Cash and cash equivalents classified as current assets		6,701,547
Cash and cash equivalents classified as noncurrent assets		5,493,070
	$	12,194,617